Oligodendroglioma epidemiology and demographics
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma epidemiology and demographics |
|
Risk calculators and risk factors for Oligodendroglioma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
Oligodendroglioma, although rare, is the third most common glioma. In adults, it constitutes about 9.4% of all primary brain and central nervous system tumors and 5%–18% of all glial neoplasms. The incidence of oligodendroglioma and anaplastic oligodendroglioma is estimated to be 0.32 and 0.17 cases per 100,000 individuals in the United States, respectively. Oligodendroglioma tends to affect the middle-aged adult population, most commonly occurring in the 4th and 5th decade of life. Median age at the time of diagnosis of oligodendroglioma is 35-47 years. Males are more commonly affected with oligodendroglioma than femaleswith male to female ratio being approximately 1.3:1. Oligodendroglioma usually affects individuals of the Caucasian race. African American, Latin American, and Asian individuals are less likely to develop oligodendroglioma.
Epidemiology and Demographics
Prevalence
- Oligodendroglioma, although rare, is the third most common glioma.[1]
- It occurs primarily in adults constituting about 9.4% of all primary brain and central nervous system tumors and 5%–18% of all glial neoplasms.[2]
- It can also be found in children comprising about 4% of all primary brain tumors.
- Oligodendroglioma and anaplastic oligodendroglioma, together are one-tenth as common as glioblastoma (most commonly occurring malignant primary brain tumor in adults).
Incidence
- Incidence of oligodendroglioma and anaplastic oligodendroglioma is estimated to be 0.32 and 0.17 cases per 100,000 individuals in the United States, respectively.[3][4]
- Approximately, 1000 oligodendroglial tumors are diagnosed each year in United States.
Age
- Oligodendroglioma is a disease that tends to affect the middle-aged adult population (adults between 25 and 45 years of age).[1]
- Oligodendroglioma most commonly occurs in the 4th and 5th decade of life.
- Median age at diagnosis of oligodendroglioma is 35-47 years.[5]
- Median age at diagnosis is approximately 5 to 10 years older for World Health Organization (WHO) grade III (anaplastic) tumors compared with WHO grade II (low-grade) tumors.
- Oligodendroglioma is occasionally diagnosed in teenagers and in adults over the age of 65 years.[6]
Gender
- Males are more commonly affected with oligodendroglioma than females.
- The male to female ratio is approximately 1.3:1.[7]
Race
- Oligodendroglioma usually affects individuals of the Caucasian race.
- African American, Latin American, and Asian individuals are less likely to develop oligodendroglioma.[8]
References
- ↑ 1.0 1.1 Epidemiology of oligodendroglioma. Dr Henry Knipe and Dr. Frank Gaillard et al. http://radiopaedia.org/articles/oligodendroglioma
- ↑ Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C; et al. (2017). "CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014". Neuro Oncol. 19 (suppl_5): v1–v88. doi:10.1093/neuonc/nox158. PMC 5693142. PMID 29117289.
- ↑ McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brännström T, Broholm H; et al. (2011). "Risk factors for oligodendroglial tumors: a pooled international study". Neuro Oncol. 13 (2): 242–50. doi:10.1093/neuonc/noq173. PMC 3064625. PMID 21149253.
- ↑ Ohgaki H, Kleihues P (2005). "Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas". J Neuropathol Exp Neurol. 64 (6): 479–89. PMID 15977639.
- ↑ Mørk SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R; et al. (1985). "Oligodendroglioma: incidence and biological behavior in a defined population". J Neurosurg. 63 (6): 881–9. doi:10.3171/jns.1985.63.6.0881. PMID 4056902.
- ↑ Morshed RA, Han SJ, Hervey-Jumper SL, Pekmezci M, Troncon I, Chang SM; et al. (2019). "Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60". J Neurooncol. 141 (2): 383–391. doi:10.1007/s11060-018-03044-4. PMID 30498891.
- ↑ Simonetti G, Gaviani P, Botturi A, Innocenti A, Lamperti E, Silvani A (2015). "Clinical management of grade III oligodendroglioma". Cancer Manag Res. 7: 213–23. doi:10.2147/CMAR.S56975. PMC 4524382. PMID 26251628.
- ↑ Patterns by Gender for Selected Histologies CBTRUS Statistical Report: NPCR and SEER Data from 2004-2006. CBTRUS.org 2015. http://www.cbtrus.org/2010-NPCR-SEER/CBTRUS-WEBREPORT-Final-3-2-10.pdf